Government updates HIV treatment guidelines
- PMID: 11367234
Item in Clipboard
Government updates HIV treatment guidelines
BETA.
1999 Jan.
Abstract
AIDS: The newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva), was added to the Department of Health and Human Services' (DHHS) "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents" as a preferred component of combination anti-HIV therapy, in 1998. Efavirenz is the first non-protease inhibitor drug to be included as a preferred agent. The other NNRTIs, nevirapine and delavirdine, are included as "alternative" recommendations. More information was added to the guidelines, including adverse effects of anti-HIV drugs and drug resistance testing. A web address for the full guidelines is provided.
Similar articles
-
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.Hopkins HIV Rep. 1998 May;10(3):5. Hopkins HIV Rep. 1998. PMID: 11365494
-
NNRTIs: a neglected class.GMHC Treat Issues. 1998 Sep;12(9):6-10. GMHC Treat Issues. 1998. PMID: 11365807
-
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.J Med Virol. 2001 Nov;65(3):445-8. J Med Virol. 2001. PMID: 11596076
-
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22. Ned Tijdschr Geneeskd. 2006. PMID: 16924943 Review. Dutch.
-
[Non-nucleoside reverse transcriptase inhibitors].Ann Med Interne (Paris). 2000 Jun;151(4):260-7. Ann Med Interne (Paris). 2000. PMID: 10922953 Review. French.
Cited by
-
Subclinical leukopenia in a cross section of Nigerian blood donors.J Blood Med. 2011;2:79-85. doi: 10.2147/JBM.S16214. Epub 2011 May 11. J Blood Med. 2011. PMID: 22287866 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical